Study characteristics
| Study . | Vaccine . | Country . | Study period (mo/y) . | Study design . | Number of patients . | Subgroup of patients (numbers) . | Age . |
|---|---|---|---|---|---|---|---|
| Avivi 2021 | BNT162b2 | Israel | 12/20-03/21 | Prospective | 171 | MM (159); SMM (12) | Median (range) 70 (38-94) |
| Bird 2021 | BNT162b2 or AZD1222 | UK | Until 03/21 | Retrospective | 93 | MM (93) | Not reported |
| Bitoun 2021 | BNT162b2 | France | 01/21-03/21 | Prospective | 27 | MM (27) | Not reported |
| Enßle 2021 | BNT162b2 | Germany | 09/20-06/21 | Prospective | 77 | MM (73); SMM (4) | Median (IQR) 67 (60-72) |
| Gavriatopoulou 2021 | BNT162b2 | Greece | 01/21-05/21 | Prospective | 35 | MM (29); SMM (6) | Median (IQR) 66 (74) |
| Greenberg 2021 | BNT162b2 or mRNA-1273 | US | 12/20-03/21 | Prospective | 44 | MM (44) | Median (IQR) 64 (57-69) |
| Henriquez 2021 | BNT162b2 | France | 01/21-06/21 | Prospective | 60 | MM (60) | Mean (range) 70 (41-92) |
| Marasco 2021 | BNT162b2 or mRNA-1273 | Italy | 03/21-05/21 | Prospective | 263 | MM (52) | Median (range) 73 (47-78) |
| Pimpinelli 2021 | BNT162b2 | Italy | Not reported | Prospective | 42 | MM (42) | Median (range) 73 (47-78) |
| Ramasamy 2021 | BNT162b2 or AZD1222 | UK | 02/21-03/21 | Prospective | 23 | MM (23) | Mean (SD) 62.9 (9.9) |
| Rehav 2021 | BNT162b2 | Israel | Not reported | Prospective | 187 | MM (187) | Median (IQR) 66 (59-73) |
| Stampfer 2021 | BNT162b2 or mRNA-1273 | US | Not reported | Prospective | 96 | MM (96); SMM (7) | Median 68 (35-88) |
| Šušol 2022 | BNT162b2 | Czech Republic | Not reported | Prospective | 119 | MM (119) | Not reported |
| Terpos 2021 | BNT162b2 | Greece | Not reported | Prospective | 48 | MM (39); SMM (9) | Median (IQR) 74 (62-80) |
| Terpos 2022 | BNT162b2 | Greece | 09/21 – 10/21 | Prospective | 167 | MM (167) | Median (IQR) 68 (60-75) |
| Study . | Vaccine . | Country . | Study period (mo/y) . | Study design . | Number of patients . | Subgroup of patients (numbers) . | Age . |
|---|---|---|---|---|---|---|---|
| Avivi 2021 | BNT162b2 | Israel | 12/20-03/21 | Prospective | 171 | MM (159); SMM (12) | Median (range) 70 (38-94) |
| Bird 2021 | BNT162b2 or AZD1222 | UK | Until 03/21 | Retrospective | 93 | MM (93) | Not reported |
| Bitoun 2021 | BNT162b2 | France | 01/21-03/21 | Prospective | 27 | MM (27) | Not reported |
| Enßle 2021 | BNT162b2 | Germany | 09/20-06/21 | Prospective | 77 | MM (73); SMM (4) | Median (IQR) 67 (60-72) |
| Gavriatopoulou 2021 | BNT162b2 | Greece | 01/21-05/21 | Prospective | 35 | MM (29); SMM (6) | Median (IQR) 66 (74) |
| Greenberg 2021 | BNT162b2 or mRNA-1273 | US | 12/20-03/21 | Prospective | 44 | MM (44) | Median (IQR) 64 (57-69) |
| Henriquez 2021 | BNT162b2 | France | 01/21-06/21 | Prospective | 60 | MM (60) | Mean (range) 70 (41-92) |
| Marasco 2021 | BNT162b2 or mRNA-1273 | Italy | 03/21-05/21 | Prospective | 263 | MM (52) | Median (range) 73 (47-78) |
| Pimpinelli 2021 | BNT162b2 | Italy | Not reported | Prospective | 42 | MM (42) | Median (range) 73 (47-78) |
| Ramasamy 2021 | BNT162b2 or AZD1222 | UK | 02/21-03/21 | Prospective | 23 | MM (23) | Mean (SD) 62.9 (9.9) |
| Rehav 2021 | BNT162b2 | Israel | Not reported | Prospective | 187 | MM (187) | Median (IQR) 66 (59-73) |
| Stampfer 2021 | BNT162b2 or mRNA-1273 | US | Not reported | Prospective | 96 | MM (96); SMM (7) | Median 68 (35-88) |
| Šušol 2022 | BNT162b2 | Czech Republic | Not reported | Prospective | 119 | MM (119) | Not reported |
| Terpos 2021 | BNT162b2 | Greece | Not reported | Prospective | 48 | MM (39); SMM (9) | Median (IQR) 74 (62-80) |
| Terpos 2022 | BNT162b2 | Greece | 09/21 – 10/21 | Prospective | 167 | MM (167) | Median (IQR) 68 (60-75) |
IQR, interquartile range; SD, standard deviation; SMM, smoldering multiple myeloma; UK, United Kingdom; US, United States.